CG Oncology, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is based in Irvine, California.

Period	PE Ratio
2024-12-31	-44.28
2025-12-31	-30.02

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CGON	$62.44	+0.88%	0.01M
3
4
5

CG Oncology, Inc. (CGON) PE Ratio

PE Ratio Data

Get CG Oncology, Inc. Data in Excel

More CGON Financial Data